Bendary 2011.

Study characteristics
Methods	Study design: randomized trial Setting/country: single center in Egypt Dates when study was conducted: January 2006 to June 2008
Participants	Ethnicity: NA Inclusion criteria Primary Ta‐T1 TCC of the bladder without CIS Exclusion criteria NA Total number of participants randomly assigned Screened: NA Eligible: 80 Disease type: primary disease Intervention: gemcitabine Number of all participants randomly assigned: 40 Age: overall mean 56.2 (SD 11.18) years Gender (men/women): NA Tumor T stage: NA Tumor grade (G1/G2/G3) or tumor grade (low/high): NA Tumor size (< 3 cm/≥ 3 cm): NA Number of tumors (1/> 1): NA Prior intravesical therapy: 0 Comparator: BCG Number of all participants randomly assigned: 40 Age: overall mean 56.2 (SD 11.18) years Gender (men/women): NA Tumor T stage: NA Tumor grade (G1/G2/G3) or tumor grade (low/high): NA Tumor size (< 3 cm/≥ 3 cm): NA Number of tumors (1/> 1): NA Prior intravesical therapy: 0
Interventions	Intervention: gemcitabine Gemcitabine 2000 mg/50 mL saline 6 weekly intravesical instillation after 2 weeks from TURBT Comparator: BCG BCG 6 × 108 CFU (strain: NA)/50 mL saline 6 weekly intravesical instillation after 2 weeks from TURBT Follow‐up: 3–18 months (mean 10.8 (SD 27) months)
Outcomes	Study did not separate the outcomes as primary and secondary. Efficacy Recurrence Progression How measured: NA Time point measured: NA Time point reported: NA Safety How measured: NA Time point measured: NA Time point reported: NA Subgroup analysis: NA
Funding Sources	None
Declarations of interest	NA
Notes	Protocol: NA Language of publication: English
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote from publication: "Random" only; abstract only. Comment: randomization stated, but no information on method used; therefore, unclear risk of selection bias.
Allocation concealment (selection bias)	Unclear risk	Comment: no information given; abstract only.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: no information given; abstract only.
Blinding of outcome assessment (detection bias) Subjective outcomes	Unclear risk	Comment: no information given; abstract only.
Blinding of outcome assessment (detection bias) Objective outcomes	Low risk	Comment: no information given; abstract only, but objective outcomes not likely affected by lack of blinding.
Incomplete outcome data (attrition bias) Time to recurrence	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Time to progression	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Grade III–V adverse events	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Time to death from bladder cancer	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Time to death from any cause	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Grade I or II adverse events	Unclear risk	Comment: no information given; abstract only.
Incomplete outcome data (attrition bias) Disease‐specific quality of life	Unclear risk	Comment: no information given; abstract only.
Selective reporting (reporting bias)	Unclear risk	Comment: no information given; abstract only.
Other bias	Unclear risk	Comment: no information given; abstract only